Appili Therapeutics, Inc. (APLIF)
0.0055
0.00 (0.00%)
USD |
OTCM |
Oct 16, 16:00
Appili Therapeutics Debt to Equity Ratio : -0.7005 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.7005 |
| March 31, 2026 | -0.7464 |
| December 31, 2025 | -0.7605 |
| September 30, 2025 | -0.7832 |
| June 30, 2025 | -0.8443 |
| March 31, 2025 | -0.9177 |
| December 31, 2024 | -0.8281 |
| September 30, 2024 | -0.7946 |
| June 30, 2024 | -0.8116 |
| March 31, 2024 | -0.7492 |
| December 31, 2023 | -0.815 |
| September 30, 2023 | -0.8253 |
| June 30, 2023 | -0.8769 |
| March 31, 2023 | -1.036 |
| December 31, 2022 | -1.016 |
| September 30, 2022 | -1.774 |
| Date | Value |
|---|---|
| June 30, 2022 | -3.302 |
| March 31, 2022 | -1.522 |
| December 31, 2021 | -6.915 |
| September 30, 2021 | -0.9126 |
| June 30, 2021 | 0.1732 |
| March 31, 2021 | 0.081 |
| December 31, 2020 | 0.0598 |
| September 30, 2020 | 0.0482 |
| June 30, 2020 | 0.0438 |
| March 31, 2020 | 0.1136 |
| December 31, 2019 | 1.385 |
| September 30, 2019 | 0.5456 |
| June 30, 2019 | 0.3478 |
| March 31, 2019 | 0.2531 |
| December 31, 2018 | 0.378 |
| March 31, 2018 | 0.2284 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| InMed Pharmaceuticals, Inc. | 0.00 |
| NervGen Pharma Corp. | 0.00 |
| Milestone Pharmaceuticals, Inc. | 7.785 |
| Clearmind Medicine, Inc. | 0.1389 |
| Lexaria Bioscience Corp. | 0.0183 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 0.9129M |
| Total Liabilities (Quarterly) | 14.32M |
| Shareholders Equity (Quarterly) | -13.41M |
| Current Ratio | 0.0653 |
| Net Debt Paydown Yield | -11.67% |